The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors.
Yousef Zakharia
No relevant relationships to disclose
Theodore S. Johnson
No relevant relationships to disclose
Howard Colman
Consultant or Advisory Role - Genentech; Roche; Sigma-Tau
Stock Ownership - Castle Biosciences
Honoraria - Merck
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Eugene Kennedy
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Ramses F. Sadek
No relevant relationships to disclose
Feng Ming Kong
Research Funding - Varian Medical Systems
John Vender
No relevant relationships to disclose
David Munn
Consultant or Advisory Role - Newlink Genetics
Stock Ownership - Newlink Genetics
Honoraria - Newlink Genetics
Research Funding - Newlink Genetics
Olivier Rixe
No relevant relationships to disclose